How ADCs Work: A Simple Guide for Patients and Caregivers

Cancer treatments have evolved greatly over the years. Traditional chemotherapy kills fast-growing cells, including both cancerous and healthy cells, which can lead to difficult side effects like hair loss, nausea, and fatigue.

Antibody-Drug Conjugates (ADCs) are a newer, smarter type of cancer treatment. They are designed to find and attack only cancer cells, reducing harm to healthy tissue and improving quality of life for patients.

What is an ADC?

An ADC works like a targeted delivery system — similar to a guided missile for cancer therapy.

It has three main parts:

1. Antibody: The “navigator” that finds and binds to cancer cells.
   

2. Payload (Drug): A very powerful drug that kills the cancer cells once delivered.
   

3. Linker: A connector that keeps the drug attached to the antibody until it reaches the cancer cell.
   
   

This design helps deliver strong treatment directly to the problem area.

How ADCs Work

Here’s how ADCs fight cancer step by step in simple terms:

1. Finding the Target:
   The antibody travels through the body and searches for cancer cells with unique markers (antigens).
   
   

2. Attaching to Cancer Cells:
   Once the antibody finds a cancer cell, it locks onto it, like a key fitting into a lock.
   
   

3. Entering the Cell:
   The cancer cell absorbs the ADC, pulling it inside.
   
   

4. Releasing the Drug:
   The linker breaks apart inside the cancer cell, releasing the powerful drug.
   
   

5. Destroying the Cancer Cell:
   The drug attacks the cancer cell from the inside, killing it while leaving most healthy cells unharmed.
   
   

Why ADCs Are Different from Chemotherapy

This precision targeting means ADCs can be more effective with fewer side effects, improving patient comfort during treatment.

Benefits for Patients

• Targeted treatment: Directly attacks cancer cells.
  

• Fewer side effects: Reduced harm to healthy cells.
  

• Powerful results: Uses highly potent drugs for tough cancers.
  

• Combination therapy: Can be used with other treatments like immunotherapy.
  

• Hope for advanced cancers: Expands treatment options where others may have failed.
  
  

Possible Side Effects

While safer than traditional chemotherapy, ADCs can still cause some side effects, such as:

• Fatigue and weakness
  

• Mild nausea or vomiting
  

• Low blood cell counts
  

• Mild infusion reactions like fever or chills
  
  

Caregiver Tip: Report any unusual or severe symptoms to the healthcare team immediately for prompt management.

Examples of Approved ADCs

Several ADCs are already approved by the FDA and used in cancer treatment, including:

• Kadcyla® (Trastuzumab emtansine): For HER2-positive breast cancer.
  

• Adcetris® (Brentuximab vedotin): For certain types of lymphoma.
  

• Enhertu® (Trastuzumab deruxtecan): For advanced breast and gastric cancers.
  
  

Many more are in clinical trials, bringing hope to patients with various cancer types.

Xcellon Biologics’ Role in ADC Development

Behind every ADC treatment is years of scientific work.

Xcellon Biologics works with biotech and pharmaceutical companies to:

• Develop precise, safe ADC designs.
  

• Optimize manufacturing and scaling processes.
  

• Ensure ADCs are ready for clinical trials and regulatory approval.
  
  

Our goal is to bring innovative, life-saving treatments to patients faster.

The Future of ADCs

ADCs are one of the fastest-growing areas of cancer research.
In the future, we may see:

• Even smarter antibodies that target multiple cancer types.
  

• Stronger, more effective drugs with fewer side effects.
  

• ADCs being used for autoimmune diseases and other conditions beyond cancer.
  
  

This progress gives patients and caregivers hope for more effective, personalized treatments.

Conclusion

Antibody-Drug Conjugates represent a powerful shift in cancer care. By delivering medicine directly to cancer cells, ADCs can improve treatment effectiveness while reducing side effects.

With ongoing research and support from companies like Xcellon Biologics, ADCs are bringing us closer to a future where cancer care is more precise, targeted, and patient-friendly.